Silence Therapeutics results in-line and eyes large fundraising
19th Mar 2014 09:15
Biotech company Silence Therapeutics increased research and development spending in 2013 and is now quite confident of completing a 'substantive' fundraising. The AIM-listed gene therapy specialist has received "encouraging indicative levels of interest and support" in discussions with several ins
Read moreMonday broker round-up UPDATE
17th Feb 2014 08:23
Aberdeen Asset Management: Goldman Sachs lowers target price from 600p to 540p, while its buy recommendation is kept. Anglo American: Deutsche Bank cuts target price from 1500p to 1460p, while leaving its hold recommendation unchanged. Credit Suisse raises target price from 1650p to 1900p upgrading
Read moreSilence Therapeutics places 9.5m shares and plans share consolidation
10th Apr 2013 09:31
Silence Therapeutics, a biotechnology company, has placed 9.5m new ordinary shares at 200p each and announced plans for a share consolidation. The placing raised net funds of £18.7m, which will be used to support the development of the RNAi platform, to broaden its skills from its pre-clinical res
Read moreSilence Therapeutics appoints Chief Medical Officer, shares rise
2nd Jan 2013 12:28
Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer. He will oversee the phase II study on ATU027 for cancer and aid in the expansion of the private biotechnology company's clinical pipelines in oncology and acute lung injury. Khan is a consultant endocrinolog
Read moreSilence Therapeutics raises five million pounds
29th Nov 2012 13:11
Biotechnology firm Silence Therapeutics announced a five million pound placing to Henderson Global Investors and Ora Capital. New shares were placed at 2.5p representing a discount of around 19% to the market price. Funds raised will be used to expand the group's research activities in short in
Read moreMitchells & Butlers Chief buys 45,800 shares
28th Nov 2012 16:45
Alistair Darby, the Chief Executive Officer of Mitchells & Butlers, the UK's largest operator of managed restaurants and pub, has boosted his holding in the group with the purchase of 45,800 shares. Darby, who only took up his current role in October, purchased the shares in two tranches; 44,716 on
Read moreSilence Therapeutics granted two US patents
19th Nov 2012 13:18
Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents. The patents, which are for both its interfering RNA molecules and lipid complexes used in drug delivery, will extend
Read moreSmall caps: IndigoVision, Silence Therapeutics, Air Partner...
31st Jul 2012 11:51
Air Partner, a provider of air charter services, has said underlying profit before tax for the year is expected to meet its forecasts. The firm's cost reduction programme is also now nearly complete and will realise 'significant cost savings' in the next financial year, with a one off restructuring
Read moreSilence eschews underwriters in discounted share issue
12th Jul 2012 10:52
Biotechnology firm Silence Therapeutics is to tap the market, offering shares at a sharp discount, as it seeks to bolster its balance sheet. The group plans to raise up to £5.7m before expenses through the issue of 940m new shares at a halfpenny each and a £1m convertible loan note issue. Of the n
Read moreSilence Therapeutics lands new partnership
27th Sep 2011 09:16
The biotech firm Silence Therapeutics has announced a partnership with what it describes as "one of the world's leading pharmaceutical companies". The agreement will see Silence work with the unnamed firm to see whether its "DACC" system for delivering compounds into target cells can be combined wi
Read moreSilence losses grow despite higher revenues
27th Apr 2011 15:53
Partnerships with big drug companies such as AstraZeneca lifted revenues at drug discovery group Silence Therapeutics in 2010, though losses also grew as it upped spending on development activities. Pre-tax losses came in at £8.8m, compared with £7.5m the previous year, on revenues that were up to
Read moreSilence boosted by partner's test results
21st Mar 2011 17:42
Silence Therapeutics recovered sharply from a 52-week low after it announced a favourable set of results from a phase II trial of a drug developed by Quark Pharmaceuticals. The Quark drug uses Silence's AtuRNAi technology. The treatment, which is intended to be used on patients with swollen retinas
Read moreSilence ends bid talks
7th Feb 2011 15:20
Shares in Silence Therapeutics have fallen by 15% after it admitted that bid talks had ended. AIM-quoted Silence originally said that it was in bid talks on 6 September 2010. The share price is not much higher than before the bid rumours started. Silence says that it received a number of indicat
Read moreSmall caps round-up: Forte Energy, Discovery Metals Proximagen...
21st Dec 2010 09:59
Uranium company Forte Energy has been testing for rare earth elements (REE) in Guinea and the latest assay results indicate "provide a higher level of encouragement that a substantial body of REE mineralisation may exist within the company's 100% owned Firawa uranium project." "REE assays from thes
Read morePositive study for Silence
10th Nov 2010 14:38
AIM-quoted Silence Therapeutics says that research shows that its lead RNA interference (RNAi) drug candidate, Atu027, prevents the spread of breast cancer to lungs. The findings were published in the latest edition of the scientific journal Clinical Cancer Research in a peer-reviewed paper entitl
Read more